非类固醇盐皮质激素受体拮抗剂在糖尿病肾病中的研究进展  

Progress of Non-steroidal Mineralocorticoid Receptor Antagonists in Dia⁃betic Nephropathy

作　　者：孙玉根 孙爱丽[1] SUN Yugen;SUN Aili(Department of Endocrinology,Shandong University Second Hospital,Jinan,Shandong Province,250033 China)

机构地区：[1]山东大学第二医院内分泌科,山东济南250033

出　　处：《糖尿病新世界》2023年第20期185-189,共5页Diabetes New World Magazine

摘　　要：糖尿病肾病是糖尿病的重要微血管并发症之一,研究显示盐皮质激素受体在糖尿病肾病的发展中起到重要作用,然而,因高钾血症、男性乳腺发育等不良反应,传统盐皮质激素受体拮抗剂的临床应用受限,近年来非类固醇盐皮质激素受体拮抗剂作为新型糖尿病肾病治疗药物受到关注。本综述介绍了盐皮质激素受体参与糖尿病肾病的病理生理学机制,并简要概述了非类固醇盐皮质激素受体拮抗剂相关临床研究进展。Diabetic nephropathy is one of the important microvascular complications of diabetes mellitus,and studies have shown that the mineralocorticoid receptor plays an important role in the development of diabetic nephropathy.However,the clinical application of traditional mineralocorticoid receptor antagonists is limited due to adverse effects such as hyperkalemia and male breast development.Non-steroidal mineralocorticoid receptor antagonists have re-ceived attention as novel therapeutic agents for diabetic nephropathy in recent years.This review describes the patho-physiological mechanisms of mineralocorticoid receptor involvement in diabetic nephropathy and briefly summarizes the progress of clinical studies related to non-steroidal mineralocorticoid receptor antagonists.

关 键 词：非类固醇盐皮质激素受体拮抗剂 2型糖尿病 糖尿病肾脏病 

分 类 号：R587.1[医药卫生—内分泌]